AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises? Maik Kemper Editor in Chief Conclusion In short, AbbVie MAVIRET…